Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

Anthony Matta; Vanina Bongard; Frédéric Bouisset; Dorota Taraszkiewicz; Jean-Pierre Rabès; Jean Ferrières

doi:10.12659/MSM.928784

07 May 2021 : Clinical Research

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

Anthony Matta^123ABCDEF*, Vanina Bongard^12ABCDEF, Frédéric Bouisset^12ABCDEF, Dorota Taraszkiewicz^12ABCDEF, Jean-Pierre Rabès^4BDEF, Jean Ferrières^12ABCDEFG

DOI: 10.12659/MSM.928784

Med Sci Monit 2021; 27:e928784

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Analysis of variance (ANOVA) comparing the reduction in mean low-density lipoprotein cholesterol between the 3 groups after adding PCSK9i.

	Mean variation in LDL-c (mg/dl±SD)	Compared to	95% CI	P value
PCSK9i	125±60	PCSK9i+statin	(−0.85; −0.15)	0.002
		PCSK9i+ezetimibe	(−0.28; 0.72)	0.86

PCSK9i+ezetimibe	103±89	PCSK9i	(−0.72; 0.28)	0.86
		PCSK9i+statin	(−1.28; −0.17)	0.006

PCSK9i+statin and ezetimibe	175±72	PCSK9i	(0.15; 0.85)	0.002
		PCSK9i+ezetimibe	(0.17; 1.28)	0.006
CI – confidence interval; HDL-c – high-density lipoprotein cholesterol; LDL-c – low-density lipoprotein cholesterol; PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitors.

Back to the Article

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

Your Privacy